Effective July 1, 2019, both PCSK-9 products for cholesterol management—Repatha and Praluent—became available for distribution through our retail and specialty pharmacy networks. They will no longer be restricted to dispensing only through the specialty network and will offer a lower non-preferred brand formulary tier designation. Pharmacies in the retail pharmacy network have been notified so that they may adjust their inventory supply to service members. All current utilization management programs will remain in place to review for coverage eligibility.